Business Wire

SLATE-ASSET-MANAGEMENT

15.9.2022 20:01:38 CEST | Business Wire | Press release

Share
Slate Asset Management Acquires Significant Minority Stake in Roswall Development Inc., a Fully Integrated Canadian Renewable Energy Company

Slate Asset Management (“Slate”), a global alternative investment platform targeting real assets, today announced a strategic partnership with Roswall Development Inc. (“Roswall”), a fully integrated Canadian renewable energy company based in Halifax, Nova Scotia, through the acquisition of a significant minority stake in the company.

Roswall is an experienced developer of renewable energy projects offering complete energy solutions for infrastructure, industries, and communities in partnership with private and public enterprises. Roswall’s full suite of services includes consulting, strategic planning, design-build installations, development, financing, and operations of renewables projects. The leadership team at Roswall has been active in the renewable energy industry for over 15 years, having successfully developed, constructed, and operated C$150 million of wind, solar, and retrofit projects across North America. Roswall was also awarded the first independent retail electricity licence in Nova Scotia in October 2021.

The partnership with Slate will help fund future renewables projects developed by Roswall, which has a significant and actionable pipeline of wind development opportunities that will support its retail operation by providing 100% clean electricity to its customers. Additionally, it has a growing turnkey business focused on commercial, institutional, and industrial markets. The Roswall team will also benefit from the global expertise, resources, and relationships of the broader Slate platform as it looks to scale its platform across Canada and North America.

“We believe that proven and scalable renewable energy solutions can meaningfully improve the resiliency of our cities and communities by reducing energy consumption, minimizing the environmental impacts of energy production, and increasing the reliability and efficiency of our energy sources,” said Christian Schmid, Managing Director and Global Head of Infrastructure at Slate. “Roswall’s experienced team has been on the front lines of the significant energy transition taking place globally over the past decade, working to broaden access to affordable, reliable, sustainable, and modern energy sources across North America. We look forward to partnering closely with the Roswall team on integrations across our own real estate portfolio and supporting their mission of continuing to accelerate the energy transition worldwide.”

Daniel Roscoe, Chief Executive Officer at Roswall, said: “The energy economy is changing at a dramatic pace. We have shown with our work in Nova Scotia and the Caribbean that locally produced renewable energy combined with energy retrofits can provide cost savings, emission reductions, and energy security. We are excited to find a likeminded partner in Slate, with the capacity and experience to grow our approach and accelerate energy transition and climate action here in Nova Scotia and abroad.”

Slate is an active investor in sustainable assets and technologies that advance the global energy transition and enable cities and communities to reach their carbon emission reduction goals. The firm recently hired Jeff Rodgers as Managing Director, North American Infrastructure to support the continued growth of Slate’s infrastructure platform globally, with a focus on uncovering investment opportunities tied to the global energy transition in the US and Canada.

About Slate Asset Management

Slate Asset Management is a global alternative investment platform targeting real assets. We focus on fundamentals with the objective of creating long-term value for our investors and partners. Slate’s platform has a range of real estate and infrastructure investment strategies, including opportunistic, value add, core plus and debt investments. We are supported by exceptional people and flexible capital, which enable us to originate and execute on a wide range of compelling investment opportunities. Visit slateam.com to learn more.

About Roswall Development Inc.

Roswall Development Inc. is an experienced developer of renewable energy projects, encompassing all aspects from financing and construction to operation. We are focused on enabling regions, industries, and public institutions to become energy self-sufficient through development of renewable energy systems and energy efficiency retrofits. Roswall's team has over 15 years of experience with over $150M of wind, solar and retrofit projects successfully developed, constructed and operated. Active in both Canada and the Caribbean, Roswall is helping accelerate the energy transition by helping companies and institutions get to zero emissions cost effectively. Learn more at roswall.ca.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005149/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye